The results suggest that simvastatin might increase intracellular calcium concentration. This effect could lead to an activation of NO synthase and cyclooxygenase pathways in endo thelial cells and to contraction in vascular smooth muscle cells. This rise in Ca2+ concentration could be due to an inhibition of isoprenoid synthesis prevented by mevalonate.
Introduction
Simvastatin is a drug widely used in the treat m ent of hypercholesterolemia. This drug is an inhibitor of the rate-determining enzyme in the biosynthesis of cholesterol, 3-hydroxy-3-methylglutaryl-coenzyme A (HM G-CoA) reductase and has proved useful in the reduction of plasma low density lipoprotein (LDL). Clinical trials have dem ostrated that inhibitors of HM G-CoA reductase decrease cardiovascular-related morbidity and mortality (Vaughan et al., 1996) .
In previous studies of our laboratory, we found that another HM G-CoA reductase inhibitor, lovastatin, was able to decrease blood pressure and had vasodilatatory effects in precontracted iso lated rat thoracic aorta (Bravo et al., 1998) . It has also been demostrated that chronic treatm ent with simvastatin was able to improve endothelial func tion in spontaneously hypertensive rats (Alvarez de Sotomayor et al., 1999) . In order to elucidate the mechanism of action of simvastatin, the direct effect of this drug was investigated in rat thoracic aortic rings.
Material and Methods

Experim ental procedure
Wistar male rats (250-300 g) were killed by a blow on the head. The descending thoracic aorta was rapidly dissected and placed in a modified Krebs-Henseleit solution (PSS), containing ( m M ) : NaCl 118, KC1 4.75, N a H C 0 3 25, M gS 04 1.2, CaCl2 1.8, KH 2 P 0 4 1.2 and glucose 11. A fter ex cess fat and connective tissue were removed, the aortas were out cut into 2 -3 mm rings. Aortic rings were m ounted under the basal tension of 1 g in 20 ml organ baths containing PSS and at tached to a force-displacement transductor (H ar vard UF-1) and the signal was recorded by a Powerlab® data acquisition system (AD Instrum ents) to measure the contractile force. The tissue bath was m aintained at 37 °C and bubbled with a 95% 0 2 -5 % C 0 2 ( v / v ) gas mixture. In some experi ments, the endothelium of the aorta was mechani cally removed by gently rubbing the inner surface. The absence of endothelium was confirmed by the absence of relaxing effects of acetylcholine (ACh allowed to equilibrate for at least 90 min prior to start of experimental procedures, and during this period the incubation media was changed every Simvastatin (2,2-dimethylbutanoate 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-l-naphthalenyl), was generously provided by Merck laboratories (New Jersey, USA). All drugs were dissolved in dimethylsulfoxide (DM SO) except N-co-nitro-Larginine and diltiazem which were dissolved in dis tilled water. The final concentration of DMSO did not significantly affect the results.
D rugs
Indomethacin (l-[/?-chlorobenzoyl]-5-methoxy- 2-methylindole-3-acetic acid), m evalonate ( d l -/ 3 - hydroxy-/3-methyl-(5-valero-lactone), N-&»-nitro-L- arginine (N5-[nitroamidino]-L-2,5-diaminopenta- noic acid), diltiazem (ds-(+)-3-(acetyloxy)-5-[2- (dimethyl-amino)ethyl]-2,3-dihydro-2-(4-meth- oxy-phenyl)-l,l-benzothiazepin-4 (5H) one) hy drochloride, cyclopiazonic acid (C2 0 H 2 0 N2 O 3 ) from
Statistical analysis
Results are expressed as mean ± SEM of six preparations obtained from different animals. Analysis of variance (ANOVA) followed by the LSD (least significant difference) test were used for statistical analysis. P values <0.05 were con sidered to indicate a significant difference. Doseresponse slopes were analysed to give the concen tration of simvastatin producing 50% of the maxi mum contractile response (E D 50) using a linear regression analysis.
Results and Discussion
Addition of cumulative concentrations of sim vastatin (1 0~7 to 1 0~4 m ) induced dose-dependent contractions in isolated rat thoracic aorta with and without endothelium, reaching maximal tension values of 1.22 ± 0.08 g and 1.94 ± 0.12 g and the E D 5 0 values were 3.46 ± 0.56 x 10-5 m and 5.41 ± 0.25 x 10-6 m , respectively. In intact aortic rings, preincubation with L-NOARG (3 x 10~5 m ) signif icantly potentiated the contractions evoked by simvastatin (E D 5 0 = 3.62 ± 0.27 x 10-6 m ) . How ever, pretreatm ent of the aortic rings with indo methacin (1 0~5 m ) decreased the curve obtained with simvastatin alone underneath the control curve reaching only 30% of the maximal effect.
In the presence of mevalonate (1 m M ) , the pro duct of HM G-CoA reductase activity, simvastatininduced contraction was almost abolished. When the experiments were carried out on endotheliumremoved preparations and in a medium containing diltiazem (1 0~6 m or 1 0~5 m ) , the curve obtained with simvastatin was significantly reduced, yield ing a higher effect at the highest dose of diltiazem assayed. Pretreatm ent with cyclopiazonic acid (3 x 1 0 -6 m ) diminished the contractile effect of sim vastatin on endothelium-intact preparations. The percent data are summarized in Table I .
The contractile effect induced by simvastatin in rat aortic thoracic rings increased when the endo thelium was removed, showing the involvement of endothelial factors in the mechanism of action of simvastatin. When NO synthase was blocked with L-NOARG, the contraction caused by simvastatin was enhanced, suggesting that NO is released in the presence of simvastatin, opposing its relaxant effect to the contraction. In this way, former expe riences have shown that NO is involved in some actions of statins (Laufs et al., 1998; Hernändez-Perera et al., 1998; Kaesemeyer et al., 1999) . The contractile effect diminished when indomethacin inhibited cyclo-oxygenase, supporting the notion of a partial participation of contracting cyclo-oxygenase-derived factors (endoperoxides and throm boxanes) in this effect. Both results together might be explained by an action of simvastatin in a corvengent point of both, NO synthase and cyclo-oxy- genase pathways, like Ca2+ increment in endothelial cell, necessary for activation of NO synthase (Moncada et al., 1991) and phospholipase A 2 (Verbeij et al., 1981) , and consequently cyclo-oxygenase. The presence of mevalonate, the metabolic product of H M G -CoA reductase (Goldstein and Brown 1990) , almost abolished simvastatin-induced con traction, indicating the involvement of mevalonate pathway. In accordance with our hypothesis, some other reports showed that in vascular smooth mus cle cells, simvastatin has been able to increase tran siently cytosolic free Ca2+ concentration, being this effect prevented by the presence of mevalonate (Ng et al., 1994; Escobales et al., 1996) .
Diltiazem, a calcium entry antagonist, and cyclo piazonic acid, a Ca2+-ATPase inhibitor, were effec tive in inhibiting the contractile response to sim vastatin, leading us conclude that both: voltageoperated Ca2+ channels and calcium released from these stores are involved in the contractile mecha nism of simvastatin. In summary, simvastatin might increase intracellular calcium concentration in both endothelial and vascular smooth muscle cells. This effect lead to an activation of NO syn thase and cyclo-oxygenase pathway in endothelial cells and to contraction in vascular smooth mus cle cells.
